This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

DBV Announces The First Reported Case Of A Long Term Sustained Effect Of Peanut Desensitization After Epicutaneous Immunotherapy (EPIT) With Viaskin(R) At The French Congress Of Allergy

  • Dr. Thierry Bourrier and Pr. Christophe Dupont present abstract showing that a peanut-allergic child from the ARACHILD study had a sustained desensitization even after one year off treatment
  • Multiple Oral Presentations on EPIT at the French Congress of Allergy

BAGNEUX, France, April 16, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new paradigm for the treatment of allergies, today announced that 4 communications were presented at the French Congress of Allergy (CFA). This year, highlights included an abstract authored by Dr. Bourrier from Pediatric Hospital in Nice (CHU-LENVAL) and Pr. Dupont from Assistance Publique Hôpitaux de Paris (AP-HP) at the CFA in Paris, April 15-18, 2014 reporting for the first time that a case subject from the ARACHILD Phase II study after an 18-month EPIT treatment maintained its desensitization level after one year off-treatment, with a strict peanut diet. A dedicated plenary session "Specific Epicutaneous Immunotherapy" will also take place at this congress on April 16 from 2:30 to 4:00 pm, and one presentation on DBV's EPIT cellular mechanism will be featured.

Summary of Poster from Dr. Bourrier and Pr. Dupont

The Abstract highlights an 8-year-old patient from the ARACHILD trial, who voluntarily stopped the EPIT treatment after reaching 1,146mg peanut protein (4 to 5 peanuts) during the 18-month food challenge, from 96,33 mg peanut protein at entry (1/3 peanut). After 12 months of no treatment and following a strict non-peanut diet, the child performed another food challenge and was able to reach again a cumulative reactive dose of 1,110 mg peanut protein. Both investigators concluded that this case is the first documented case in humans of a persistent efficacy induced by EPIT despite a continued and prolonged absence of exposure with the allergen after immunotherapy.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs